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Abstract
This chapter discusses application of natural parasites of bacteria, bacteriophages 
(phages), as a promising biological control for Salmonella in poultry and swine. 
Many studies have shown phages can be applied at different points from farm-to-
fork, from pre to post slaughter, to control the spread of Salmonella in the food chain. 
Pre-slaughter applications include administering phages via oral gavage, in drinking 
water and in feed. Post slaughter applications include adding phages to carcasses and 
during packaging of meat products. The research discussed in this chapter demon-
strate a set of promising data that relate to the ability of phages to reduce Salmonella 
colonisation and abundance. Collectively the studies support the viability of phage 
as antimicrobial prophylactics and therapeutics to prevent and control Salmonella in 
the food chain.
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1. Introduction
The global problem of antimicrobial resistance (AMR) is driving the search 
for novel treatments to control multidrug-resistant (MDR) pathogenic bacteria. 
Infections caused by MDR pathogens impose a significant burden on healthcare 
systems and economic productivity and are a major cause of mortality. Globally, 
AMR is associated with 700,000 deaths annually, with the prospect of this reaching 
10,000,000 by 2050 if no resolution is found [1].
A One Health approach, that considers the intrinsic associations between 
antibiotic use in livestock and agriculture, the emergence of MDR pathogens, 
and the societal impact of AMR in developed and developing nations is required 
[2, 3]. However, integrating these approaches is challenging as antibiotic use in 
agriculture is generally widespread [4, 5]. For example, prophylactic administra-
tion of antibiotics to pigs during the weaning process is a standard technique 
employed in many countries [6]. Over recent years, efforts to limit antibiotic 
use other than specifically to control active bacterial infections have been 
implemented. Consequently, the use of antibiotics as growth promoters in food 
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production animals was banned in the European Union (EU) in 2006 and in the 
United States of America (USA) in 2017 [7].
Gram negative Enterobacteriaceae are an important component of human, 
animal, and environmental microbiomes and can be associated with both health 
and disease. While the family contains several notorious pathogens (e.g. certain 
E. coli, Klebsiella spp., Shigella spp. etc.), the genus Salmonella presents a problem 
for AMR due to its ubiquitous distribution in food production environments and 
MDR phenotypes [8]. Worryingly, clinically important antibiotics are becoming 
ineffective, including colistin, which is a human critical antibiotic [9]. As such, 
alternative strategies to control/eliminate MDR Salmonella that may replace or 
complement antibiotics are needed.
Globally, dominant Salmonella serovars display a distribution pattern in pigs 
and poultry reflective of each industry. In pigs, S. Typhimurium (e.g. U288, U302, 
DT193, DT104), monophasic 4,[5],12:i:- and other variants such as 4,12:i:- are 
the dominant strains at both farm and slaughterhouse facilities in the UK and EU 
[10–13]. Other serovars such as S. Derby, S. Enteritidis, S. Bovismorbificans, S. 
Kedougou, S. Rissen, and S. Brandenburg are also reported [13, 14]. In the USA 
and China the dominant Salmonella serovars include S. Typhimurium, monophasic 
4,[5],12:i:- S. Infantis, and S. Brandenburg [15].
For poultry, and in parallel with the global emergence of strains such as 4, 
[5],12:i:- the most prevalent serovar in UK production facilities is an S. Typhimurium 
derivative 13,23:i:- that accounted for almost a quarter of all isolations in 2019 [13]. 
Across the EU, the USA and China monophasic strains continue to expand through-
out poultry production facilities. Other serovars such as S. Enteritidis, S. Berta, S. 
Typhimurium, S. Infantis, S. Hadar, S. Kentucky, and S. Heidelberg have all been 
isolated and/or linked to outbreaks [16–18]. The global diversity of Salmonella spp. 
within pig and poultry production constitutes a significant source of disease for 
humans and animals alike.
Controlling Salmonella requires intervention strategies capable of implementa-
tion at the national/international level. One such strategy is the targeted application 
of natural bacterial predators, bacteriophages (phages). Over the last decade, a 
robust body of evidence has demonstrated that phages can be applied at various 
points from farm-to-fork for pathogen control [19, 20]. Phage application could be 
implemented at the stage of rearing [21, 22], slaughter and processing [23], or at 
pre-retail/packaging [24, 25].
2. Phages
Phages are viruses that specifically infect and kill bacteria and with few reported 
side-effects in humans and animals. Phages are the most abundant biological entity 
on Earth, with estimated numbers ten times greater than bacterial cells [26]. Phages 
were independently discovered by Frederick Twort and Felix d’Herelle in 1915 
and 1917 respectively. D’Herelle was the first to test phage efficacy in animals and 
showed phage treatment increased the survival of chickens suffering from fowl 
typhoid by 95–100% compared with 0–25% in untreated birds [27]. Despite this, 
phage therapy research slowed markedly following the discovery of antibiotics. 
However, research into phage therapy has been renewed since the emergence of 
AMR as it offers a promising alternative to antibiotics. Studies have shown phages 
are able to lyse MDR strains [28, 29] and there are multiple examples of success-
ful phage therapy in humans [30] and animals [31]. Furthermore, phages can be 
applied to food to reduce bacterial loads and globally are being used commercially 
to improve food safety [32].
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2.1 Phage morphology and infection cycle
Phages are characterised based on their virion morphology, genome type and 
sequence, and the infection cycle they follow. Phages are approximately a hundred 
times smaller than bacterial cells by volume, and generally only infect a subset 
of strains within a host species. Over 5,000 phages have been viewed under the 
transmission electron microscope (TEM) [33] and over 96% of phages studied are 
tailed phages and belong to the order Caudovirales. Siphoviruses, myoviruses and 
podoviruses are the most common phage types and constitute 61, 25 and 14% of all 
isolated tailed phages respectively (Figure 1) [34].
Phages are obligate parasites of bacteria as they lack the capacity to replicate 
independently. Phage replication occurs through either a lytic or lysogenic cycle 
(Figure 2). Phages following the lytic cycle attach to receptor(s) on the host cell 
surface using tail fibres, after which they inject their DNA and sequester the host’s 
metabolic processes to produce more phage, eventually leading to cell lysis and release 
of the virions for further cycles of infection [35]. In comparison, during the lysogenic 
cycle phage DNA is incorporated into the bacterial cell and is replicated along with 
the host. Under certain conditions, e.g. stress and DNA damage, the phage can enter a 
lytic cycle as above. The lifestyle of the phage is determined via sequencing where the 
absence of recognisable integrases and other genes involved in the process of integra-
tion can be taken as indicative of a strictly lytic life cycle [36]. As lytic phages kill their 
target cells directly, they are preferred for therapeutic applications.
Figure 1. 
Morphology of tailed phages viewed under TEM. The images show the typical structure of a (a) siphovirus, 
(b) myovirus and (c) podovirus. TEM images were taken by the Electron Microscopy Facility at the University 
of Leicester.
Figure 2. 
Phage lytic and lysogenic infection cycle. (a) phages attach to a receptor on the bacterial cell, after which  
(b) they inject their DNA (red line) into the cytoplasm of the cell. Phages can then go on to follow the lytic cycle 
(c-d) or the lysogenic cycle (f-g). In the lytic cycle (c) phages take over the host cells machinery to replicate their 
nucleic acids and proteins (d) to form new phage progeny. This (e) leads to lysis of the bacterial cell to release 
the phage progeny and the phages go on to infect more target bacterial cells. In the lysogenic cycle (f) phage DNA 
is integrated into the bacterial genome and (e) as the bacterial cells are replicated the prophage is replicated 
simultaneously.
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2.2 Phage isolation, host range and resistance
Phages can be isolated from any environment their hosts inhabit. Salmonella-
specific phages have been isolated from faecal material obtained from pig and 
chicken farms, food processing plants, wild boar reserve [29], slurry lagoons [37], 
and sewage [22, 23]. Consequently, as phages are found in nature, humans and 
animals are continuously exposed to them, which is a major advantage in using 
them, as new entities would not be introduced into biological systems when phages 
are applied therapeutically [38].
The lytic spectrum (host range) of a phage is determined by screening against 
multiple strains of the target pathogen. Both narrow and broad host range phages 
have potential uses as therapeutics [39], for example a highly-specific, narrow 
host range phage can be applied with minimal perturbation to other residual 
microbial populations. Broad host-range phages provide a better scope of lysis 
and are therefore the desired components of most phage therapeutic applications. 
Multiple phages can be combined as a cocktail to improve phage coverage of the 
target species [40].
Emergence of resistance against therapeutic phages is a possibility as both 
phages and bacteria are in a continuous arms race. The mechanisms of phage 
resistance include altering the phage receptor, blocking phage DNA injection or 
inhibiting phage replication. This resistance can be countered by using cocktails of 
phage which bind to different receptors, as its unlikely resistance to all phage in the 
cocktail will emerge concurrently. Moreover, phage resistance can lead to a fitness 
cost for the bacterial cells [41]. Different multiplicities of infections (MOI’s), which 
is ratio of phages to bacterial cells can also be trialed to limit resistance [42].
3. Experimental phage studies in chickens and pigs
In this section, the application of phages pre- and post-slaughter to reduce 
Salmonella numbers in chickens and pigs is discussed. Studies have varying levels 
of success in reducing Salmonella in challenge models, but with each study, valuable 
information is gained on phage dose, route of administration and resistance.
3.1 Experimental phage studies in chickens
3.1.1 In vivo phage studies in chickens at farm level
One of the first studies that investigated phage therapy against Salmonella chal-
lenged chickens dates back to 1991 [43]. The authors orally challenged one day old 
Rhode Island Red chickens with S. Typhimurium (108 Colony Forming Units (CFU)) 
and 10 minutes later administered a single phage orally at dose 1012 Plaque Forming 
Units (PFU)/mL. The mortality of untreated chickens was 56% 21 days post-chal-
lenge but in chickens treated with phage mortality was reduced to 20%. The authors 
demonstrated phage transition and replication in the gut at sites of Salmonella coloni-
zation such as the crop, intestine and caecum. Similarly, Atterbury et al. [21] showed 
in two different broiler chicken studies phage treatment (1011 PFU/mL) administered 
two days after challenge (108 CFU/mL), reduced ceacal colonisation by 4.2 and 2.2 
log10 CFU/mL in birds challenged with Enteritidis P125109 or Typhimurium 4/74 
respectively after 48 hours.
Goncalves and colleagues [44] compared the efficacy of three different phage 
cocktails in 45-day-old broiler chickens. The phages were administered at a 
dose of 109 PFU/mL via oral gavage, 1 hour post challenge with S. Enteritidis at 
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107 CFU/mL. Two of the three phage cocktails reduced caecal Salmonella counts 
by ~2 log10 CFU/mL in 12 hours, and Salmonella counts were below the detectable 
limit in the crop.
Toro et al. [45] designed a cocktail of three phages which could infect the top 
seven serotypes commonly associated with chickens. This cocktail was administered 
orally on days 4, 5, 6, 18, 19 and 20 at a dose of 5.4 × 106 PFU/bird and birds were 
challenged on day 7 with S. Typhimurium (105 CFU/mL). The phage treatment 
reduced Salmonella colonisation in the caeca by ten-fold, 4 days post-challenge, and 
48 hours after treatment phages were isolated in the birds’ faeces. Interestingly, the 
authors found phage treatment had a beneficial effect and chickens given the treat-
ment gained more weight in comparison to challenged birds.
Delivering phages to chickens individually, via oral gavage, would be impractical 
commercially, however they could be administered easily through drinking water. 
Clavijo and colleagues [46] added a six-phage cocktail (named SalmoFREE®) at 
dose of 108 PFU/mL to drinking water on days 18, 26 and 34 (chickens were slaugh-
tered on day 35), which was sufficient to reduce ceacal Salmonella counts to below 
the detectable limit (below 100 CFU/mL). The trial was conducted at a commercial 
farm where there was a record of Salmonella outbreaks and included 34,680 broiler 
chickens. This is the biggest and the only trial to date evaluating phage efficacy 
against Salmonella in a commercial setting. There was no difference in mortality or 
productivity measurements between untreated control birds and those treated with 
phage only, suggesting the cocktail was safe. Furthermore, the authors conducted 
a microbiome study and showed phage treatment had no detrimental effect on the 
chicken’s microbiota [47]. Their studies provide further valuable evidence into the 
effectiveness and safety of phage treatment.
Delivering phages as feed additives has been investigated. Sklar and Joerger. 
[48] added a single phage dose (A) and a three-phage cocktail (B) to starter broiler 
feed at a dose of 107 PFU/g. The treated feed was available throughout the trial and 
chickens were challenged with S. Enteritidis at 104 CFU on day 1. After 14 days 
phage A reduced caecal colonisation by 1.9 log10 CFU/g and cocktail B by 0.6 log10 
CFU/g. The authors found that the process of mixing phage with feed and storing 
feed in bird rearing conditions over 14 days caused a 2 log10 PFU/g reduction in 
phage numbers. Phage stability in feed could be a limitation and further research is 
needed to determine the impact storage conditions have on phage stability, such as 
factors as humidity and temperature.
3.1.2 Experimental post-slaughter phage studies in chickens
Following processing and packaging, meat is refrigerated to avoid bacterial 
growth, but Salmonella can survive under these conditions and phages could be 
used to reduce surface contamination of Salmonella. Goode et al. [38] applied 
a single phage to chicken skin artificially contaminated with S. Enteritidis at 
103 CFU/cm3. Phage applied at doses above 105 PFU/mL reduced bacterial numbers 
by over 98% and phages amplified on the surface of the infected skin by three-fold 
over 48 hours. In comparison, in the uninfected samples the phage titre reduced 
by 1 log10 PFU/cm
3, which suggests phages don’t linger in absence of their target 
pathogen.
Atterbury et al. [49] showed phage treatment at dose 109 PFU/mL reduced levels of 
S. Enteritidis and S. Typhimurium by 72.2% and 38.9% respectively on spiked chicken 
skin samples (106 CFU/ml). The authors confirmed phage infection was occurring on 
the surface of the chicken skin by spreading a bioluminescent S. Typhimurium strain 
on the surface of chicken skin and then monitored its growth using photon counting. 
Further studies have shown the efficacy of phage treatment to reduce Salmonella 
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numbers on chicken skins are comparable to the typical chemical agents used by the 
food industry [50]. In addition, combining phage and chemical treatment was able to 
further decrease Salmonella counts to below detection levels [51].
To date only one study has investigated phage application on whole carcasses. 
Higgins et al. [52] spiked chicken carcasses with S. Enteritidis at 20 CFU, after which 
carcasses were sprayed with phage at different doses. The authors found only high 
phage doses of 108 and 1010 PFU/ml were effective and after 24 hours, Salmonella 
was only isolated from one out of fifteen carcasses. The phage counts were not 
monitored in the study, therefore it’s unclear if there was phage amplification.
Phage treatment of raw meat samples has been shown to be effective at reduc-
ing bacterial load and consequently reducing its presence in the final consumer 
product. Duc et al. [53] tested the lytic activity of a five-phage cocktail at dose 109 
PFU on chicken breasts inoculated with either S. Enteritidis or S. Typhimurium at 
105 CFU. The phage cocktail reduced counts of both strains by ~1.6 log10 CFU/piece 
of chicken breast, when stored at 8°C, over 24 hours. However, when the meat was 
stored at 25°C phage treatment was more effective and reduced S. Enteritidis or S. 
Typhimurium by 3.1 and 2.2 log10 CFU/piece respectively over 24 hours. This could 
suggest phage activity is temperature dependent. However, another study showed 
phage activity was unaltered when spiked chicken breasts (105 CFU/ml) were 
treated with phage at doses 106 and 107 PFU/mL and stored at 4°C and 25°C. Under 
both conditions, phage treatment reduced bacterial counts to undetectable levels 
after just 12 hours [54]. The studies suggest phage temperature stability can vary 
between phages and its stability needs to be tested to determine which are more 
effective at food storage temperatures.
3.2 Experimental phage studies in pigs
3.2.1 Phage therapy in pre-market and market-weight pigs
Very few studies have examined the efficacy of phage treatments to control 
Salmonella in live pigs and this is largely due to the inherent difficulties of per-
forming longitudinal studies from piglets to finished pigs. One pioneering study 
did exactly that and the efficacy of a fifteen-phage cocktail were tested in chal-
lenged piglets and market-weight pigs [22]. In the first study, the phage cocktail 
(109 PFU/mL) and challenge strain S. Typhimurium γ4232 (5 × 108 CFU/pig) were 
co-administered via oral gavage to piglets. Piglets were euthanised 6 hours post-
inoculation in order to mimic the amount of time spent in a holding pen. Overall, 
the activity of the phage cocktail was sufficient to achieve 2–3 log10 CFU (~99%) 
reductions in the ileum, tonsils and caecum. In collected ileum and caecal samples, 
in five out of six phage-treated pigs S. Typhimurium counts were reduced to below 
the limits of detection (~100 CFU/mL).
The authors next assessed the efficacy of the phage cocktail in market-
weight pigs. Four pigs (in three replicates) were inoculated via oral gavage with 
5 × 109 CFU S. Typhimurium and allowed to contaminate a holding pen for a 
period of 48 hours. Following this, sixteen naïve pigs (non-Salmonella infected 
– eight phage-treated/eight mock treatments controls) were introduced to the 
holding pens and allowed to co-mingle with the seeder pigs for 6 hours. Phage 
cocktail administration involved an initial oral gavage of 109 PFU/mL followed 
by further identical doses every 2 hours for a total of 6 hours. After 6 hours of 
co-mingling between S. Typhimurium γ4232-infected, phage cocktail-treated, 
and mock control-treated pigs, each cohort was euthanised. In phage treated 
pigs there was 1 to 1.5 log10 CFU/mL reductions in Salmonella colonisation in 
ceacal and ileal samples. The role phages can play in controlling Salmonella 
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infection in pigs at a critical stage of the production process is evident from the 
work performed by Wall et al. [22].
A similar degree of efficacy was observed when applying a microencapsulated 
phage cocktail treatment to control shedding of S. Typhimurium during a hold-
ing period of 6 hours [55]. Saez et al. found that shedding of Salmonella from 
pigs in the phage-treated group (PT) was less common than non-phage treated 
pigs (nPT) at 2 hours (% pigs shedding PT-38.1%, nPT-71.4%) and 4 hours 
(PT-42,9% - nPT-81.1%). Sampling of caecal and ileal contents 6 hours post-
infection showed that phage-treated pigs had significantly less S. Typhimurium 
levels at both anatomical sites by 1 log10 CFU/mL. Another study produced some 
promising results by showing how dietary supplementation with probiotics 
(Saccharomyces cerevisiae, Lactobacillus acidophilus, and Bacillus subtilis) and 
phages can positively influence growth performance of pigs. A phage cocktail 
(~109 PFU/g) designed to target a diverse selection of bacteria (S. Typhimurium, 
S. Enteritidis, S. Choleraesuis, S. Derby, Staphylococcus aureus, Escherichia coli, and 
Clostridium perfringens types A and C) was administered as part of a feed supple-
ment. Interestingly, the addition of phage was found to be more effective than 
probiotics. Phages may therefore offer an attractive alternative to replace the use 
of antibiotics as growth promoters in pigs [56].
3.2.2 Phage decontamination of pigskin
Post-slaughter application of phages has the potential to reduce risks associated 
with pork contaminated with Salmonella prior to general retail. An investigation 
into the stability of phages at retail temperatures (fresh 4°C and frozen −20°C) and 
also their ability to control the endemic UK pig pathogen S. Typhimurium U288 was 
examined [23]. Hooton et al. tested killing activity of Salmonella-specific phages 
against a diverse panel of Salmonella serovars prior to formulation as a four phage 
cocktail (PC1). PC1 consisted of three novel Salmonella phage isolates (ΦSH17, 
ΦSH18, and ΦSH19) combined with the broad-host range Salmonella phage Felix 
01 in equal volumes/titres for a final concentration of 108 PFU/mL. Initially it was 
shown that both S. Typhimurium U288 and the phage components of PC1 are 
both stable on experimentally-contaminated pigskin pieces stored at temperatures 
reflective of those at retail. The efficacy of PC1 was subsequently tested on spiked 
pigskin over a five-day trial under fresh conditions (4°C). A 3 × 3 matrix of CFU 
(106, 104, and 103) versus PC1 PFU (107, 105, and 104) was used to examine a range 
of MOIs (0.01–10,000) to determine the most effective combination.
The phage cocktail applied at MOI’s of 1000 (107 PC1 V 104 U288) and 10 (105 
PC1 v 104 U288) reduced S. Typhimurium U288 levels by ~92% after 1 hour post 
challenge. After 48 hours Salmonella counts were significantly reduced by ~1.4 
log10 CFU/4 cm
2. The first reductions of S. Typhimurium U288 below the limits of 
detection were also reported at the 48 hour timepoint, specifically when an MOI 
of 10 was employed against low level contamination. At 96 hours post-inoculation 
it was evident that MOIs in excess of the target bacterium could reduce low-level 
bacterial contamination to below the limits of detection. The results reported here 
indicate that phages may provide useful tools for the post-harvest reduction of S. 
Typhimurium U288 on pork products [23].
4. Commercial phage products
A handful of phage products that target Salmonella in pre- and post- slaughter 
stages of the food chain are commercially available and summarized in Table 1.  
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Some products (SalmoFresh® and SalmoPro®) have already obtained clearance from 
specific regulatory agencies, such as FDA, and are available to purchase, while others 
are patented but not approved by any regulatory authority, at the time of writing. 
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5. Phage/antibiotic synergy (PAS)
The efficacy of combinatorial medicinal treatments is well-documented and have 
proven successful in treating a range of human diseases such as cancer, HIV, and 
malaria [59]. Similarly, the use of phages and antibiotics synergistically (PAS) has 
been explored and experimental studies have shown using phages and antibiotics 
in combination could enhance bacterial suppression and lower emergence of bacte-
rial resistance. Furthermore, a combined approach can lead to re-establishment 
of antibiotic sensitivity, for example in cases where phages bind to bacterial drug 
efflux pumps [60]. In vitro studies have investigated PAS activity for the control of S. 
Typhimurium with the well-studied phage P22 and antibiotics ceftriaxone and cip-
rofloxacin. The study found pre-treatment of S. Typhimurium with phage P22 prior 
to antibiotic addition was the most effective approach in comparison to treating with 
phages 6 hours after antibiotic treatment [61]. The timing and order of phage and 
antibiotics needs to be considered as it can influence PAS activity. It was also reported 
that the presence of antibiotics did not negatively influence phage binding to 
Salmonella cells, and a significant increase in phage lytic activity was observed [62].
To date, no in vivo PAS studies have been conducted in Salmonella challenged 
chickens and pigs. Therefore, further in vivo work is required for the underly-
ing dynamics of PAS to be understood and developed into useful combinatorial 
therapies. Within the context of phage therapeutics in agricultural settings (and 
potentially in the clinic) PAS may well provide an exciting route of research for 
development into a parallel treatment with antibiotics. The emergence of resistance 
from the target bacterium to both antibiotics and phage treatment, choice of antibi-
otics and phage combinations, and potential efficacy-improving interactions with 
immunological responses will be important factors for consideration [59].
6. Potential challenges of using phages in poultry and pigs
The use of phages against Salmonella in farming, either pre or post-slaughter, 
have some challenges. Some of those difficulties are common to phage therapy in 
general and fall in to four categories initial phage selection; phage delivery; resis-
tance development; and regulatory approval.
6.1 Phage selection
On the initial phage selection, potential phage candidates need to be virulent 
and propagate via the lytic cycle as opposed to temperate (can propagate via lyso-
genic or lytic cycle), which need to be confirmed by sequencing. This is to ensure 
the phage will not integrate on host genome avoiding transduction and horizontal 
gene transfer [21, 63, 64].
6.2 Phage delivery
The topic of phage therapy pharmacodynamics and pharmacokinetics is com-
plex and more specific reviews have recently been published on this topic [65, 66]. 
In brief, phages need to reach the site of bacterial colonisation, and in poultry and 
pigs, Salmonella initially colonises the gut. Many studies have been designed to 
establish if phages can be delivered to the gastrointestinal tract and beyond via oral 
administration, either in feed or drinking water. For post-slaughter application, 
phage preparations can be applied by directly applying to carcasses, meat, skin, 
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packaging materials as well as surfaces in the abattoir or meat processing facilities. 
Both pre- and post-slaughter applications present challenges to phage delivery [36].
A particular challenge to phages delivered orally to control Salmonella is to 
ensure they will be active in the gut pH, despite the fact that they are sensitive 
biological entities and will encounter changes in pH (Figure 3) and temperature. 
Phages are typically stable between pH 4 and pH 10 [67]. However, the studies dis-
cussed in Section 3 highlight natural phages retain lytic activity through the passage 
of the gut and do reach the focal point of infection.
Alternative solutions have been developed to protect phages from the acidic 
conditions by using dry or liquid formulation solutions. For example, it was shown 
that Felix O1 microencapsulation in chitosan-alginate microspheres could fully 
preserve phage viability upon 1 hour exposure to simulated gastric fluid (pH = 2.4 
with 3.2 mg ml−1 pepsin) and 3 hour exposure to 2% (wt/vol) porcine bile extract 
[68]. Other studies have shown that liposome-encapsulated phages (UAB_Phi20, 
UAB_Phi78, and UAB_Phi87) were significantly more stable in simulated gastric 
fluid (pH = 2.8 with 3.0 mg ml − 1 pepsin) when compared to free phages in vitro 
while the preparation was stable at 4°C for at least 3 months [69]. These data show 
that the challenge of gut pH range that the phage has to endure, when administered 
orally, can be overcome by selecting phages that remain viable and withstand wide 
pH variations or, in addition or as an alternative, shield the phages by means of pH 
resistant pharmaceutical formulation development.
6.3 Overcoming phage resistance
Phages are no different from other antimicrobials that are used to kill bacteria, 
and can become resistant to them following exposure. Often, the use of phage 
cocktails and rotation schedules is used to limit or avoid the development of resis-
tant mutants. When phages are used post-slaughter as disinfectants, they can be 
deployed at a high titer, to reduce the build up of phage-resistant bacteria [70]. In 
order to reduce the accumulation of phages on surfaces after their intended use in 
Figure 3. 
The gastrointestinal pH changes in the gut of pigs and chickens.
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the food industry, some disinfectants were tested and proved to be successful at 
neutralizing phages, such as peracetic acid [71].
When using phages within farm settings the challenge of phage persistence, 
spread and resistance development is more significant because successive animals 
will be housed in the same facilities and disinfection must be thorough. A recent 
study using a patented six phage cocktail against Salmonella (SalmoFREE) showed 
that after the first trial, SalmoFREE phages were detected from the beginning 
of the second trial in treated and control groups houses, showing that even after 
the cleaning and disinfection process, phages persisted in the environment and 
survived between trials. As a consequence, birds in the second trial (control and 
treatment group) showed unexpected reduction of Salmonella counts even before 
treatment/placebo administration at day 17 [46].
Effective disinfection practices and phage cocktail rotation may be the solution 
to the phage persistence challenge, however the effect of disinfectants should be 
tested on a case-by-case basis to determine their efficacy at neutralizing the respec-
tive phage(s) cocktail [72].
6.4 Regulating phage products
As discussed above, phages may be used as a feed additive to prevent or treat 
infection, as a medicine to treat infection or as a post product treatment for 
carcasses or meat. Phages could also be used to decontaminate either the environ-
ment that the animals are living in, or facilities regarding production of the final 
product. Phages go through specific regulatory pathways depending on which of 
these intervention points that they are used in, and on the level of claims associ-
ated with their use. To take a product to market requires the developer to know 
which regulatory route they will take, in order to gather appropriate data on safety 
and efficacy [73].
In recent years there has been a significant amount of engagement from regulat-
ing bodies, who are also acutely aware of the need to find novel antimicrobials. 
They are also aware that this is often seen as a major hurdle to developing the 
technology and are keen to help. It is important to state that by working with 
regulators there is an opportunity to impose a regulatory system that will allow 
the exploration of this technology whilst hopefully mitigating against many of the 
mistakes that we have previously made in terms of overusing antibiotics from the 
outset. Antibiotic stewardship was largely implemented after extensive bacterial 
resistance to antibiotics had already been achieved however sensible regulation 
could work hand in hand with a stewardship program to maintain effective phage 
use for future generations [74].
Establishing how phages fit into traditional drug/veterinary medical product 
regulatory systems is not always trivial. In the USA, phages are regulated by the 
Food and Drug Administration (FDA), regardless as to whether they are to be used 
in humans or animals, although they go through different parts of this depending 
on exactly how they are being used. Interestingly the FDA regulates phages in the 
same way regardless of whether they are ‘natural’ or engineered [73].
In Europe phages are currently regulated by the European Commission through 
the European Medicines Agency. Unlike the system in the USA, if phages are 
genetically altered, they are regulated differently. In the UK if phages are to be used 
within animals, they are regulated by the Veterinary Medical Directorate but if their 
end use is in humans they are regulated by the Medicines and Healthcare products 
Regulatory Agency and in food they are regulated by the Food Standards Agency. 
The different regulatory authorities do communicate with each other to identify 
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commonalities and routes forward. Clearly there are parallels with other biologi-
cals such as monoclonal antibodies, which will inform how phages are effectively 
regulated [73].
7. Future work: machine learning tools
Phage characterisation based on host range analysis, studying phage host 
interactions, phage infection kinetics and designing phage cocktails is resource-
intensive. Machine learning (ML) based tools can be developed to predict these 
interactions, and the application of computational biology, artificial intelligence 
(AI) and modelling in phage research is rapidly developing [75]. The combination 
of these techniques with high-throughput Next Generation Sequencing promises 
greater insights into phage biology alongside the development of new tools to 
address previously intractable problems in phage therapy [76]. Computational tools 
applied to phage research are based on:
1. Homology-based methods: comparing the features (e.g. DNA/RNA/protein 
sequences) of an unknown phage with comparable information from databases 
of known phage. Examples include HostPhinder [77], VirHostMatcher [78] 
and ILMF-VH [79].
2. Machine Learning (ML) methods: these use combinations of algorithms and 
statistical techniques such as logistic regression and support vectors to find 
patterns in large datasets which are then used to make predictions [80].
3. Deep Learning (DL) methods: a subset of machine learning in which the key 
features used for pattern recognition and classification are identified by the 
computer algorithm directly and do not require human input [81].
A key aim of these approaches, as applied to phage therapy, is to facilitate or 
automate the matching of phages to target bacterial pathogens. This would revo-
lutionize the field as it would reduce or eliminate the need for extensive host range 
profiling in the laboratory and would allow the rapid countering of resistance.
Homology-based methods have been used more extensively than ML so far, but 
more for the identification and annotation of phage DNA from metagenomic data 
than for phage host matching. Homology-based approaches have used genomic 
similarity (e.g. HostPhinder [77]), oligonucleotide frequency (e.g. VirHostMatcher 
[77]), and phage abundance profiling [82]. However, the success of these methods 
varies widely, with correct identification of the host to genus or species level only 
occurring between 9.5% and 75% of the time.
Phage host matching using ML has also met with varied success. Approaches 
include using chemical parameters of all phage and host proteins [80], or focusing 
on a subset of these, such as receptor binding proteins [75], which have accurately 
predicted phage hosts 30 to 90% of the time. Relatively few studies have used DL 
methods. As with the homology-based methods above, some studies have focused 
on the use of DL to identify and separate phage sequences from metagenomic data. 
DL was used by Li et al. [79] to accurately to match phage and host species 81% of 
the time using 27 features of phage and host proteins.
A disadvantage of ML and DL is that large datasets are required, and these are 
often skewed heavily towards phage which infect a small number of well-studied 
bacteria. For example, in one study approximately 86% of phage used in the ML 
model infected a single species (M. smegmatis). Moreover, DL methods are not 
13
Potential Roles for Bacteriophages in Reducing Salmonella from Poultry and Swine
DOI: http://dx.doi.org/10.5772/intechopen.96984
readily interpretable and regarded as ‘black boxes’ due to the lack of human involve-
ment in feature selection and application. Additionally, even the best performing 
ML and DL models are currently unable to predict phage hosts at the strain level, 
which will a necessary step in real-world therapeutic applications.
Phage host matching is likely to be more useful when using phage therapy for 
highly diverse pathogens, such as Salmonella and E. coli, than for more homogenous 
bacteria such as Staphylococcus aureus. ML and DL have the potential to automate 
the process of phage selection of their predictions are shown to be reliable, and 
potentially in the future could help design personalised phage therapeutics for 
human and agricultural use.
8. Conclusions
Phages could provide a natural alternative to traditional antimicrobial therapies 
in pig and poultry production. Multiple intervention points exist from farm-to-fork 
allowing for the development of targeted phage therapeutic strategies. The promising 
results obtained from diverse experimental approaches demonstrate the potential 
of phages to reduce Salmonella in live animals, as well as in finished retail products. 
With correct stewardship, phages may well become an integrated solution in live-
stock production especially within the remit of controlling significant pathogens 
such as Salmonella. While some products have made it to market, current legislation 
needs further development prior to widespread acceptance of phage therapeutics in 
animals and on retail products. The next generation of phage research is set to take 
advantage of developments in the fields of machine-based learning and other com-
putationally oriented approaches. Such exciting techniques may offer a more refined 
approach towards the application of phages for elimination of Salmonella from pig 
and poultry production.
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